12943_2020_1130_MOESM3_ESM.pdf (9.03 MB)
MOESM3 of Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness
journal contribution
posted on 2020-01-12, 04:53 authored by Sandra Muñoz-Galván, Blanca Felipe-Abrio, Eva M. Verdugo-Sivianes, Marco Perez, Manuel Jiménez-García, Elisa Suarez-Martinez, Purificacion Estevez-Garcia, Amancio CarneroAdditional file 3 : Figure S1. Copy number alterations and expression of miR-30b. Figure S2. Downregulation of MYPT1 decreases Hippo pathway activation. Figure S3. Downregulation of MYPT1 increases tumorigenesis and resistance to platinum in ovarian cancer in vivo and in vitro. Figure S4. Representative images of MYPT1, NF2 and YAP immunostaining. Figure S5. Downregulation of MYPT1 increases stemness in ovarian cancer. Figure S6. CSC surface markers are increased upon MYPT1 depletion. Figure S7. Downregulation of MYPT1 increases resistance to platinum treatment by inhibiting the Hippo pathway.